Efficacy of sulfadiazine and pyrimetamine for treatment of experimental toxoplasmosis with strains obtained from human cases of congenital disease in Brazil

Silva, Letícia Azevedo; Fernandes, Matheus Delgado; Machado, Anderson Silva; Reis-Cunha, João Luís; Bartholomeu, Daniella Castanheira; Vítor, Ricardo Wagner Almeida

doi:10.1016/j.exppara.2019.05.001

Cited by 28 publications

(23 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pyrimethamine associated with sulphadiazine has been the treatment available and indicated for severe cases for a long period (Silva et al, 2019). Both drugs inhibit folate metabolism in the parasite, acting directly on tachyzoites (acute phase of infection); however, this does not eradicate cystic forms (chronic phase of infection) (Konstantinovic et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Moringa oleiferaextract promotes apoptosis-like death inToxoplasma gondiitachyzoitesin vitro

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Moringa oleiferaextract promotes apoptosis-like death inToxoplasma gondiitachyzoitesin vitro

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This is of interest since humans will be more and more in contact with such strains coming from the wild biotope, especially in South America, as demonstrated by the increasingly diverse genotypes reported from congenital toxoplasmosis in South America [ 35 ]. In addition, Brazilian Toxoplasma strains would require higher pyrimethamine or sulfadiazine dosages, and sulfadiazine-resistant isolates were identified [ 36 , 37 , 38 ].…”

Section: Discussionmentioning

confidence: 99%

A Histone Deacetylase (HDAC) Inhibitor with Pleiotropic In Vitro Anti-Toxoplasma and Anti-Plasmodium Activities Controls Acute and Chronic Toxoplasma Infection in Mice

Jublot

Cavaillès

Kamche

et al. 2022

IJMS

View full text Add to dashboard Cite

Toxoplasmosis is a highly prevalent human disease, and virulent strains of this parasite emerge from wild biotopes. Here, we report on the potential of a histone deacetylase (HDAC) inhibitor we previously synthesized, named JF363, to act in vitro against a large panel of Toxoplasma strains, as well as against the liver and blood stages of Plasmodium parasites, the causative agents of malaria. In vivo administration of the drug significantly increases the survival of mice during the acute phase of infection by T. gondii, thus delaying its spreading. We further provide evidence of the compound’s efficiency in controlling the formation of cysts in the brain of T. gondii-infected mice. A convincing docking of the JF363 compound in the active site of the five annotated ME49 T. gondii HDACs was performed by extensive sequence–structure comparison modeling. The resulting complexes show a similar mode of binding in the five paralogous structures and a quite similar prediction of affinities in the micromolar range. Altogether, these results pave the way for further development of this compound to treat acute and chronic toxoplasmosis. It also shows promise for the future development of anti-Plasmodium therapeutic interventions.

show abstract

“…However, genotyping of the parasite strain involved may be an important addition to the diagnosis, particularly if atypical strains are suspected, as infection with different strains / strain types may require different therapeutic approaches. Treatment of acute symptomatic toxoplasmosis and/or different dosing regimens have been suggested for infection with atypical strains [33,40], and it is to be hoped that in the near future more options will become available to tailor treatment according to the infecting strain.…”

Section: Discussionmentioning

confidence: 99%

Postnatal ocular toxoplasmosis in immunocompetent patients

Lijeskić

Štajner

Srbljanović

et al. 2021

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Ocular toxoplasmosis is the most common cause of infectious posterior uveitis worldwide. It can be prenatal or postnatal in origin. Despite estimations that postnatal ocular toxoplasmosis is more prevalent, only several cases of proven postnatal ocular toxoplasmosis have been reported in non-epidemic settings. Here, the clinical evolution of ocular toxoplasmosis of conclusively proven postnatal origin in immunocompetent patients is reported. Methodology: Postnatal ocular toxoplasmosis was diagnosed based on clinical diagnosis supported by the longitudinal detection of Toxoplasma gondii-specific IgG, IgM and IgA antibodies in the serum as well as by direct detection of the parasite (bioassay) and/or its DNA (real-time PCR) in aqueous humor. Results: Three cases involved adults in whom ocular toxoplasmosis developed during primary T. gondii infection, as part of the clinical presentation in two and as the sole manifestation in one patient. The fourth patient was a case of inactive ocular toxoplasmosis in a 14-year-old boy, where postnatal infection was confirmed by exclusion of maternal infection. The causative parasite strain was genotyped in only one case and it belonged to genotype II, the dominant type in Europe. One patient acquired the infection in Africa, suggesting an atypical strain. Conclusions: The distinction between prenatal and postnatal ocular toxoplasmosis is only possible in particular clinical situations, and requires extensive laboratory investigation. Genotyping of the parasite strain involved may be important, particularly if atypical strains are suspected, requiring tailored treatment approaches.

show abstract

Efficacy of sulfadiazine and pyrimetamine for treatment of experimental toxoplasmosis with strains obtained from human cases of congenital disease in Brazil

Cited by 28 publications

References 27 publications

Moringa oleiferaextract promotes apoptosis-like death inToxoplasma gondiitachyzoitesin vitro

Moringa oleiferaextract promotes apoptosis-like death inToxoplasma gondiitachyzoitesin vitro

A Histone Deacetylase (HDAC) Inhibitor with Pleiotropic In Vitro Anti-Toxoplasma and Anti-Plasmodium Activities Controls Acute and Chronic Toxoplasma Infection in Mice

Postnatal ocular toxoplasmosis in immunocompetent patients

Contact Info

Product

Resources

About